Page 33 - Demo

CUAJ %u2022 FEBRUARY 2025 %u2022 VOLUME 19, ISSUE 2 31Fractional CO2 laserfor Peyronie%u2019s disease4. Moreland RB, Nehra A. Pathophysiology of Peyronie%u2019s disease. Int J Impot Res2002;14:406-10. https://doi.org/10.1038/sj.ijir.39008755. Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie%u2019s lesion. J Urol 1997;157:285-90. https://doi.org/10.1016/s0022-534765361-86. Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie Disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207. https://doi.org/10.1016/j.juro.2013.01.0877. Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie%u2019s disease and congenital penile curvature. Can Urol Assoc J 2018;12:E197-E209. https://doi.org/10.5489/cuaj.52558. Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie%u2019s disease. BJU Int2014;113:704-13. https://doi.org/10.1111/bju.125659. Levine LA. Treatment of Peyronie%u2019s disease with intralesional verapamil injection. J Urol1997;158:1395-1399.10. Ralph DJ. The surgical treatment of Peyronie%u2019s Disease. Eur Urol 2006;50:196-8. https://doi.org/10.1016/j.eururo.2006.05.01611. Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: The results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014;260:519-29; discussion 529-532. https://doi.org/10.1097/SLA.000000000000089312. Rivers JK, Zarbafian M. Improvement of Dupuytren Disease after treatment with a fractionated CO2 laser. Dermatol Surg Off Publ Am Soc Dermatol Surg Al 2021;47:153-4. https://doi.org/10.1097/DSS.000000000000215913. Majid I, Imran S. Efficacy and safety of fractional CO2 laser resurfacing in nonhypertrophic traumatic and burn scars. J Cutan Aesthetic Surg 2015;8:159-64. https://doi.org/10.4103/0974-2077.16727614. Update on Fractional Laser Technology. J Clin Aesthetic Dermatol 2010;3:42-50.15. Hultman CS, Edkins RE, Wu C, et al. Prospective, Before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013;70:521. https://doi.org/10.1097/SAP.0b013e31827eac5e16. Qu L, Liu A, Zhou L, et al. Clinical and molecular effects on mature burn scars after treatment with a fractional CO laser. Lasers Surg Med 2012;44:517-24. https://doi.org/10.1002/lsm.2205517. Shindel AW, Sweet G, Thieu W, et al. Prevalence of Peyronie%u2019s Disease-like symptoms in men presenting with Dupuytren Contractures. Sex Med 2017;5:e135-e141. https://doi.org/10.1016/j.esxm.2017.06.00118. Sheng M, Chen Y, Li H, et al. The application of corticosteroids for pathological scar prevention and treatment: current review and update. Burns Trauma 2023;11:tkad009. https://doi.org/10.1093/burnst/tkad00919. Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. Lasers Surg Med 2013;45:135-140. https://doi.org/10.1002/lsm.2212020. Gonzalez AC de O, Costa TF, Andrade Z de A, et al. Wound healing - A literature review. An Bras Dermatol 2016;91:614-20. https://doi.org/10.1590/abd1806-4841.2016474121. Issler-Fisher AC, Waibel JS, Donelan MB. Laser modulation of hypertrophic scars: Technique and practice. Clin Plast Surg 2017;44:757-766. https://doi.org/10.1016/j.cps.2017.05.00722. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie%u2019s disease plaque: A long-term single-blind study. Urology 1998;51:620-626. https://doi.org/10.1016/s0090-429500700-023. Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie%u2019s Disease. Eur Urol 2007;51:640-647. https://doi.org/10.1016/j.eururo.2006.10.04224. Hellstrom WJG, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie%u2019s disease. J Urol 2006;176:394-398. https://doi.org/10.1016/S0022-534700517-925. Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of Interferon-%u03b12b improves penile curvature in men with Peyronie%u2019s Disease Independent of Plaque Location. J Urol2015;194:1704-7. https://doi.org/10.1016/j.juro.2015.06.09626. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie%u2019s disease. J Urol 2006;175:2115-8; discussion 2118. https://doi.org/10.1016/S0022-534700270-927. Carriere SP, Pytell JD, Saltzman AF, Fuselier HA. Peyronie%u2019s Disease: A historical perspective. Am J Mens Health 2014;8:434-9. https://doi.org/10.1177/155798831452095128. Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie%u2019s Disease. J Urol 2002;168:1075-9. https://doi.org/10.1016/S0022-534764578-829. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology1983;21:584-5. https://doi.org/10.1016/0090-429590197-830. Cipollone G, Nicolai M, Mastroprimiano G, et al. [Betamethasone versus placebo in Peyronie%u2019s disease]. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol1998;70:165-8.CORRESPONDENCE: Dr. Jason K. Rivers, Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada; jason@pacificderm.ca